Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by SanFrancisco99on Jul 08, 2014 12:34am

218 Views

Post# 22723653

RE:RE:RE:RE:DO BLOOD LEVELS OF APOA-1 REALLY MATTER SO MUCH????

Thank you, Bear. I think that makes sense.

One small point I have to add: I do recall DM making a point in a recent Webcast (not sure which one) that said that RVX-208 raised APOa1 in 3 or 4 human studies - and only just missed in the 4th.

So I'm sure RVX would agree with the contention that 208 raises APOa1....

All of this brings up a bigger point: There's a ton of data we don't have. Someday it would be helpful if management would share a much larger amount of their data with retail stockholders. Of course, this is just wishful thinking. I would fall off my seat if this actually happened. Ever.

Bullboard Posts

Dynamic Funds Launches new ETF series on the TSX